News
OCGN
1.320
0.00%
0.000
Ocugen: Two Gene Therapy Data Readouts In 2024 To Drive Value
Seeking Alpha · 16h ago
Ocugen Says It Has Completed Dosing of Subjects With Geographic Atrophy In Cohort 2 Of Phase 1/2 ArMaDa Clinical Trial Of OCU410—A Modifier Gene Therapy
Benzinga · 1d ago
OCUGEN ANNOUNCES DOSING COMPLETION OF SUBJECTS WITH GEOGRAPHIC ATROPHY IN COHORT 2 OF PHASE 1/2 ARMADA CLINICAL TRIAL OF OCU410—A MODIFIER GENE THERAPY
Reuters · 1d ago
Ocugen stock jumps after $175M securities filing
Seeking Alpha · 2d ago
OCUGEN INC FILES FOR MIXED SHELF OF UP TO $175 MLN - SEC FILING
Reuters · 2d ago
OCGN Stock Earnings: Ocugen Beats EPS for Q4 2023
Ocugen reported earnings per share of -4 cents for the fourth quarter of 2023. The company reported revenue of $6.04 million. Ocugen's results were above the analyst estimate for EPS of -6 cents. The stock was down 1.7% after the market closed.
Investorplace · 3d ago
OCUGEN, INC. Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023
Press release · 3d ago
3 Standout Penny Stocks to Watch This April
Penny stocks are stocks that trade for less than $5 per share. Ocugen, Inc. (OCGN), Veru Inc (VERU), and Desktop Metal, Inc (DM) are three outperforming penny stocks trading under $2. Veru Veru stock has surged 82.6% on a YTD basis, but is 31% below its 52-week high.
Barchart · 4d ago
Weekly Report: what happened at OCGN last week (0408-0412)?
Weekly Report · 5d ago
The 'Undercovered' Dozen From March 2024
Home Stock Ideas Quick Picks & Lists The 'Undercovered' Dozen From March 2024. The "Undercovered" Dozen series highlights 12 ideas from the previous month on stocks that receive limited coverage on Seeking Alpha. B2Gold Corp. Has been covering the sale of its shares.
Seeking Alpha · 04/12 18:30
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
Ocugen, Inc. Is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines. Dr. Shankar Musunuri will participate in a fireside chat during the Emerging Growth Virtual Healthcare Equity Conference. The conference will take place from April 17 – 18, 2024.
Barchart · 04/12 06:30
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Ocugen, Inc. Incorporated Investors – OCGN
Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of securities of Ocugen, Inc. Between May 8, 2020 and April 1, 2024. The lawsuit seeks to recover damages for ocugen investors under the federal securities laws. A class action has already been filed.
Barchart · 04/11 11:09
Ocugen says EU backs a U.S. trial for gene therapy
Healthcare Ocugen says EU backs a U.S. Trial for gene therapy candidate, OCU400. Company hopes to obtain regulatory approval for the company’s gene therapy in 2026 for rare eye disorder retinitis pigmentosa. Ocugen shares traded higher on Wednesday after the company said EU backed a u.S.-based trial.
Seeking Alpha · 04/10 14:20
The Law Offices of Frank R. Cruz Announces Investigation of Ocugen, Inc. (OCGN) on Behalf of Investors
The Law Offices of Frank R. Cruz announces an investigation of Ocugen, Inc. On behalf of investors concerning the Company’s possible violations of federal securities laws. On April 1, 2024, Oc Eugen disclosed that it had identified certain accounting errors. The Company's stock price fell 10.4% on April 2, 2024.
Barchart · 04/10 14:13
OCUGEN INC: POSITIVE SCIENTIFIC ADVICE FROM EMA IS IN ALIGNMENT WITH U.S. FDA CLEARANCE OF IND AMENDMENT
Reuters · 04/10 11:02
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
Ocugen, Inc. Is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines. The European Medicines Agency reviewed the study design of the pivotal OCU400 clinical trial for retinitis pigmentosa. The EMA accepted the U.S.-based trial for submission of a marketing authorization application.
Barchart · 04/10 06:02
OCUGEN LOSS ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Inquire About Securities Class Action Investigation – OCGN
Rosen Law Firm is preparing a class action seeking recovery of investor losses. Ocugen, Inc. May have issued materially misleading business information to the investing public. The Rosen Law Firm was ranked No. 1 by ISS for securities class action settlements. The firm is investigating potential securities claims on behalf of shareholders of Oc Eugen, Inc (NASDAQ: OCGN)
Barchart · 04/09 19:00
Analysts Offer Insights on Healthcare Companies: Staar Surgical (STAA), Ocugen (OCGN) and Moderna (MRNA)
TipRanks · 04/09 12:10
BUZZ-U.S. STOCKS ON THE MOVE-Perpetua Resources, Huntington Bancshares, FuelCell Energy
Wall Street's main stock indexes advanced in choppy trading on Monday. The Dow Jones Industrial Average was up 0.10% at 38,942.47. The top three S&P 500 percentage gainers were Albemarle, Tesla and Tesla. Boeing and Boeing Co were among the biggest decliners.
Reuters · 04/08 18:05
Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study
NASDAQ · 04/08 16:13
More
Webull provides a variety of real-time OCGN stock news. You can receive the latest news about Ocugen Inc through multiple platforms. This information may help you make smarter investment decisions.
About OCGN
Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. The Company's technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. It is developing COVAXIN, which is a whole-virion inactivated intramuscular COVID-19 vaccine candidate for the North American market. It is also developing a inhaled mucosal vaccine platform, which includes OCU500, a bivalent COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and bivalent COVID-19 vaccine. Its modifier gene therapy platform is focused on addressing various retinal diseases, including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), and Stargardt disease, with a single mutation-agnostic therapy.